Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Acadia Pharmaceutica
(NQ:
ACAD
)
19.02
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Acadia Pharmaceutica
< Previous
1
2
3
4
5
6
7
8
Next >
Why Acadia Pharmaceuticals Stock Is Soaring Today
July 14, 2023
Investors are cheering Acadia's latest news.
Via
The Motley Fool
Acadia's Newest Drug Just Obliterated Sales Expectations; Shares Hit Two-Year High
July 14, 2023
The company also expanded its commercial rights to the drug and added another to its line-up.
Via
Investor's Business Daily
UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday
July 14, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Why Are Acadia Pharmaceuticals Shares Trading Higher Today?
July 14, 2023
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher after the company expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American
Via
Benzinga
Why Aehr Test Systems Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
July 14, 2023
Gainers Ainos, Inc. (NASDAQ: AIMD) shares surged 108.2% to $1.52 in pre-market trading after gaining around 7% on Thursday.
Via
Benzinga
Where ACADIA Pharmaceuticals Stands With Analysts
July 11, 2023
Via
Benzinga
11 Analysts Have This to Say About ACADIA Pharmaceuticals
June 14, 2023
Via
Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
June 14, 2023
Via
Benzinga
Microsoft To Rally Around 17%? Here Are 10 Other Analyst Forecasts For Friday
July 14, 2023
Keybanc boosted the price target for Spotify Technology S.A. (NYSE: SPOT) from $180 to $205. Keybanc analyst Justin Patterson maintained an Overweight rating. Spotify shares rose 0.9% to $172.68 in...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
July 14, 2023
It's time to start the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
Why These 2 Biotech Stocks Made Big Moves Late Thursday
July 13, 2023
Markets kept powering higher on the day.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
July 13, 2023
Via
Benzinga
ACADIA Pharmaceuticals's Return On Capital Employed Insights
May 23, 2023
Via
Benzinga
What 22 Analyst Ratings Have To Say About ACADIA Pharmaceuticals
May 09, 2023
Via
Benzinga
ACADIA Pharmaceuticals's Earnings: A Preview
May 05, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
June 29, 2023
Via
Benzinga
Strategic Fit of ACP-101 Promises Future Revenue Growth for Acadia Pharmaceuticals: Analyst
June 14, 2023
Tuesday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced the addition of a new Phase 3 development candidate to its rare disease portfolio, ACP-101 (intranasal carbetocin), for hyperphagia (a false...
Via
Benzinga
3 Penny Stocks That Could Skyrocket in the Next 12 Months
June 07, 2023
Find the top penny stocks to buy, and you can make a fortune. Pick the wrong one and there are also plenty of horrors.
Via
InvestorPlace
Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying
May 25, 2023
Although US stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
Top 5 Health Care Stocks That Should Keep You Up At Night
May 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
April 14, 2023
Via
Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
March 20, 2023
Via
Benzinga
Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment
March 13, 2023
Via
Benzinga
Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher
April 17, 2023
ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else?
Via
Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug
March 14, 2023
The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older.
Via
Benzinga
Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday
March 14, 2023
Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on...
Via
Benzinga
1 Top Biotech Stock to Buy in March
March 07, 2023
This biotech could land a major regulatory approval this month.
Via
The Motley Fool
Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...
Via
Benzinga
3 Nasdaq Stocks on Watch This Week
March 12, 2023
These three Nasdaq stocks are poised to make big moves in the coming week.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.